Focus

Pharma Investors: Angels and VC Firms

The RaiseHunt database lists 3,592 Pharma investors: 100 angel investors and 3,492 people at 1,040 firms. Most list Seed and Series A among their stages; the largest hubs are New York, London and Paris.

Strongest in New York, London and Paris

Common stages: Seed and Series A

3,592
Pharma investors
100
Angel investors
3,492
People at VC/PE firms
1,040
Firms tagged

Skip the browsing. Let AI find your ideal investors in one minute.

Paste your startup website and AI picks your best-fit investors out of 135,000+ profiles.

3,592 Pharma investors

Showing 1-20

Filters
Peter Keen
Peter Keen

Independent Investment Committee member

Cambridge, United Kingdom
Angel
FinTechHealthcare
View profile
Brennen Hodge
Brennen Hodge

operator angel

Operator angel
HealthcareSaaS
View profile
Noah Rhodes
Noah Rhodes

angel investor

Little Rock, United States
Angel
Healthcare
View profile
Bill Cherman
Bill Cherman

angel investor and operator angel

San Francisco, United States
AngelOperator angel
ConsumerHealthcare
View profile
Adam Hentze
Adam Hentze

angel investor

Chicago, United States
Angel
FinTechHealthcare
View profile
Grace Lee
Grace Lee

angel investor

Angel
ConsumerHealthcare
View profile
Edward Richman
Edward Richman

angel investor

Angel
ConsumerEducation
View profile
Benjamin Lightburn
Benjamin Lightburn

angel investor and operator angel

Vancouver, Canada
AngelOperator angel
FoodHealthcare
View profile
Gregory Macosko
Gregory Macosko

angel investor

New York, United States
Angel
ConsumerHealthcare
View profile
Aaron Michel
Aaron Michel

angel investor and operator angel

United States
AngelOperator angel
AICommerce
View profile
Japan
AngelSyndicate / Angel group
Healthcare
View profile
Durham, United States
Private equityVenture debt
Healthcare
View profile
Joerg Feldmann
Joerg Feldmann

Genesys Solution Partner

Cologne, Germany
Corporate VCVenture capital
AIHealthcare
View profile
London, United Kingdom
Private equity
FinTechHardware
View profile
William Crowder
William Crowder

Co-Founder & Managing Partner

Philadelphia, United States
Venture capital
AIFinTech
View profile
Nicole J Walker
Nicole J Walker

Advisor, Executive Committee

Chicago, United States
AcceleratorVenture capital
HealthcareSaaS
View profile
Dima Kuzmin
Dima Kuzmin

Managing Partner

London, United Kingdom
Syndicate / Angel groupVenture capital
FinTechHardware
View profile
Alain Huriez
Alain Huriez

Chairman & Managing Partner

Paris, France
Venture capital
Healthcare
View profile
Boston, United States
Private equityVenture capital
FinTechHealthcare
View profile
Sausalito, United States
Venture capital
Healthcare
View profile

900 of 3,592 Pharma investors, A to Z

Grouped by first letter. Name and profile link only, the detailed rows are in the table above.
Show

A79

B36

C61

D53

E32

F24

G27

H19

I11

J120

K37

L28

M87

N21

O6

P28

Q6

R46

S79

T50

U3

V6

W12

X10

Y13

Z6

Frequently asked questions

How many Pharma investors are on RaiseHunt?

RaiseHunt currently lists 3,592 Pharma investors.

Are Pharma investors angels or funds?

Both. 100 are angel investors putting in their own money, and 3,492 are people making investment decisions at 1,040 firms.

Where are most Pharma investors based?

The largest concentrations are in New York, London and Paris.

What stage do Pharma investors invest at?

Most list Seed and Series A among the rounds they take part in.

How do I contact Pharma investors?

Every profile shows whether an email address is on file. The addresses themselves, along with AI matching and outreach, are in the RaiseHunt app.

Is the list of Pharma investors free to browse?

Yes. The directory and every profile page are free to read. Matching your own startup against them requires an account.

Do Pharma investors only back Pharma companies?

No. A focus area is a signal of interest, not a restriction. Investors usually list several, and the useful question is whether their existing portfolio looks like the kind of company you are building.

What do investors look at first?

The team and the problem, in that order, before the product. Early on there is rarely enough traction to argue from numbers alone, so the question they are answering is whether these particular people are likely to work this problem out.

Should I raise from one investor or several?

Several, in almost every case. A single backer concentrates the risk of the round collapsing if that one conversation goes cold, and a group brings more introductions later. Rounds are usually assembled from a lead plus others who follow.

How do I follow up without being annoying?

Follow up with new information rather than a reminder. A short note saying what changed since you last wrote gives the reader a reason to reply, where "just checking in" gives them none. Two or three of those, spaced out, is normal and expected.

What if no Pharma investor replies?

Usually the list was too short or too loosely matched, not that the company is unfundable. Widen it, tighten who you are writing to, and rewrite the first two lines of the message. Those lines decide whether anything below them gets read.

What is the difference between an angel investor and a VC fund?

An angel invests their own money and can decide alone, which usually makes the process shorter. A fund invests money it raised from other people, so it answers to those backers and normally runs a longer diligence process before it commits. Founders often raise from angels first and bring in a fund once there is more to show.

Data: RaiseHunt investor dataset · Snapshot 26 September 2026 · How this data is built · Report a correction or request removal